Stock Analysis on Net

Johnson & Johnson (NYSE:JNJ)

$24.99

Economic Value Added (EVA)

Microsoft Excel

Paying user area


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Johnson & Johnson, economic profit calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 29, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2024 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The financial data indicates several notable trends over the five-year period examined. Net operating profit after taxes (NOPAT) initially increased from 13,736 million US dollars in 2020 to a peak of 18,861 million US dollars in 2021. Subsequently, NOPAT declined in 2022 to 16,117 million US dollars and experienced a more significant decrease in 2023 to 8,905 million US dollars. There was a moderate recovery in 2024 with NOPAT rising to 11,461 million US dollars, though it remained below the earlier peak.

The cost of capital remained relatively stable throughout the period, fluctuating slightly between 9.35% and 9.5%. This suggests that the company’s required rate of return was consistent and did not materially impact investment appraisal or financial performance expectations over time.

Invested capital followed a fluctuating pattern. It started at 98,344 million US dollars in 2020, marginally decreased to 98,066 million US dollars in 2021, then rose sharply to 113,818 million US dollars in 2022. This was followed by a decline to 99,118 million US dollars in 2023 and a subsequent increase in 2024 to 106,513 million US dollars. The variations in invested capital may reflect changes in the company’s investment strategy, asset base, or capital management over the years.

Economic profit, which measures value creation beyond the cost of capital, exhibited considerable volatility. It more than doubled from 4,544 million US dollars in 2020 to 9,627 million US dollars in 2021, coinciding with the peak in NOPAT. However, economic profit declined to 5,417 million US dollars in 2022 and turned negative in 2023, reporting a loss of 507 million US dollars, indicating that the company failed to cover its cost of capital during that year. In 2024, economic profit rebounded to 1,435 million US dollars but remained significantly lower than the highs in earlier years.

Overall, the financial performance showed strong profitability and value creation in the early years, peaking in 2021, followed by a downturn in 2023 with signs of gradual recovery in 2024. The negative economic profit in 2023 suggests challenges in achieving returns above the company’s cost of capital during that period. Variations in invested capital indicate dynamic capital deployment strategies that may have influenced profitability and economic profit trends.


Net Operating Profit after Taxes (NOPAT)

Johnson & Johnson, NOPAT calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 29, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Net earnings
Deferred income tax expense (benefit)1
Increase (decrease) in allowances for doubtful accounts2
Increase (decrease) in equity equivalents3
Interest expense, net of portion capitalized
Interest expense, operating lease liability4
Adjusted interest expense, net of portion capitalized
Tax benefit of interest expense, net of portion capitalized5
Adjusted interest expense, net of portion capitalized, after taxes6
Interest income
Investment income, before taxes
Tax expense (benefit) of investment income7
Investment income, after taxes8
(Income) loss from discontinued operations, net of tax9
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in allowances for doubtful accounts.

3 Addition of increase (decrease) in equity equivalents to net earnings.

4 2024 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

5 2024 Calculation
Tax benefit of interest expense, net of portion capitalized = Adjusted interest expense, net of portion capitalized × Statutory income tax rate
= × 21.00% =

6 Addition of after taxes interest expense to net earnings.

7 2024 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

8 Elimination of after taxes investment income.

9 Elimination of discontinued operations.


The financial data reveals significant fluctuations across the analyzed periods in key profitability indicators. Net earnings demonstrated an overall volatile pattern, with a marked increase from 14,714 million US dollars in 2020 to a peak of 35,153 million in 2023, followed by a sharp decline to 14,066 million in 2024. This trend suggests periods of substantial profit growth interrupted by a sudden reduction in the latest year.

Similarly, Net Operating Profit After Taxes (NOPAT) followed a comparable trend but with less pronounced peaks and troughs. Starting at 13,736 million US dollars in 2020, NOPAT increased steadily to 18,861 million in 2021, then decreased to 16,117 million in 2022, sharply dropped to 8,905 million in 2023, and slightly recovered to 11,461 million in 2024. The dip in 2023 is noteworthy, indicating operational challenges or increased costs impacting profitability before partial recovery.

Net Earnings Trend
Initial steady growth followed by a significant peak in 2023 and subsequent sharp decline in 2024.
NOPAT Trend
General growth with moderate fluctuations until 2022, a steep decrease in 2023, and a modest rebound in 2024.
Comparison between Net Earnings and NOPAT
Net earnings portray higher volatility, while NOPAT reflects more stability but still impacted by operational difficulties in 2023.
Implications
The 2023 period represents a critical year where operational profitability suffered a significant setback, potentially due to external factors or internal inefficiencies. The rebound in NOPAT in 2024, although positive, remains below earlier highs, suggesting ongoing challenges.

Cash Operating Taxes

Johnson & Johnson, cash operating taxes calculation

US$ in millions

Microsoft Excel
12 months ended: Dec 29, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Provision for taxes on income
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense, net of portion capitalized
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).


Provision for taxes on income
The provision for taxes on income demonstrates notable variability over the five-year period. It started at 1,783 million US dollars at the end of 2020, increased moderately to 1,898 million in 2021, and then saw a considerable surge to 3,784 million in 2022. This sharp increase was followed by a significant decline to 1,736 million in 2023. In 2024, it rebounded to 2,621 million, indicating some recovery but remaining below the 2022 peak. This pattern suggests fluctuations in taxable income or changes in tax regulations affecting the provision amounts.
Cash operating taxes
Cash operating taxes show a consistent upward trend from 2020 to 2023, starting at 2,949 million US dollars and rising steadily through the years to reach a peak of 5,700 million in 2023. However, in 2024, cash operating taxes decreased to 4,692 million, representing a reduction compared to the previous year but still above the earlier years. This pattern highlights increasing tax cash outflows over time with a slight moderation in the most recent year, which could reflect changes in cash tax payments or timing differences.

Invested Capital

Johnson & Johnson, invested capital calculation (financing approach)

US$ in millions

Microsoft Excel
Dec 29, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Loans and notes payable
Long-term debt, excluding current portion
Operating lease liability1
Total reported debt & leases
Shareholders’ equity
Net deferred tax (assets) liabilities2
Allowances for doubtful accounts3
Equity equivalents4
Accumulated other comprehensive (income) loss, net of tax5
Adjusted shareholders’ equity
Construction in progress6
Current marketable securities7
Invested capital

Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of allowance for doubtful accounts receivable.

4 Addition of equity equivalents to shareholders’ equity.

5 Removal of accumulated other comprehensive income.

6 Subtraction of construction in progress.

7 Subtraction of current marketable securities.


Total reported debt & leases
The total reported debt and leases demonstrated variability over the five-year period. Starting at 36,366 million USD in 2020, the figure decreased moderately to 34,751 million USD in 2021, indicating a reduction in debt obligations. However, a significant increase occurred in 2022, rising sharply to 40,959 million USD. This was followed by a notable reduction to 30,432 million USD in 2023, representing the lowest level in the period observed. In 2024, there was a rebound to 37,834 million USD, suggesting some re-leveraging or new debt acquisitions towards the end of the period.
Shareholders’ equity
Shareholders' equity showed a general upward trend with some fluctuations. It increased substantially from 63,278 million USD in 2020 to 74,023 million USD in 2021. The equity continued to grow but at a slower pace, reaching 76,804 million USD in 2022. In 2023, there was a decline to 68,774 million USD, indicating a possible payout, loss, or other equity-reducing activity during that year. Nevertheless, equity rebounded slightly to 71,490 million USD in 2024, suggesting partial recovery or capital retention.
Invested capital
Invested capital showed mixed trends across the same timeframe. It started at 98,344 million USD in 2020 and remained almost flat in 2021 at 98,066 million USD. In 2022, a significant rise to 113,818 million USD was recorded, representing a peak in capital investment. This was followed by a considerable decrease to 99,118 million USD in 2023, approaching the earlier levels of 2020 and 2021. The invested capital increased again in 2024 to 106,513 million USD, reflecting renewed capital deployment or asset acquisition activities.
Overall Analysis
The financial data reveals a pattern of volatility in debt and invested capital, while equity generally increased but with some retrenchment in the middle of the period. The fluctuations in total reported debt & leases and invested capital suggest dynamic capital structure management and investment strategy adjustments over the five years. The trends imply that the company might have been actively balancing between leveraging for growth and deleveraging to maintain financial stability. The changes in shareholders’ equity reflect underlying operational results and capital transactions during this period, with a temporary decline offset by subsequent recovery.

Cost of Capital

Johnson & Johnson, cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Borrowings3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2024-12-29).

1 US$ in millions

2 Equity. See details »

3 Borrowings. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Borrowings3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2023-12-31).

1 US$ in millions

2 Equity. See details »

3 Borrowings. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Borrowings3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in millions

2 Equity. See details »

3 Borrowings. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Borrowings3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in millions

2 Equity. See details »

3 Borrowings. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Borrowings3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in millions

2 Equity. See details »

3 Borrowings. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Johnson & Johnson, economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 29, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2024 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


Economic Profit
The economic profit exhibited a generally fluctuating trend over the five-year period. It increased substantially from 4,544 million US dollars in 2020 to a peak of 9,627 million US dollars in 2021, indicating strong value creation during this period. However, in 2022, economic profit declined sharply to 5,417 million US dollars, followed by a significant negative value of -507 million US dollars in 2023, suggesting a period of value destruction or operational challenges. A partial recovery was observed in 2024, with economic profit returning to a positive 1,435 million US dollars, although this remains considerably lower than the peak in 2021.
Invested Capital
Invested capital showed variability with no clear upward or downward trend. It slightly decreased from 98,344 million US dollars at the end of 2020 to 98,066 million US dollars in 2021, then increased notably to 113,818 million US dollars in 2022. This increase could be indicative of higher investments or acquisitions during that year. The invested capital subsequently decreased to 99,118 million US dollars in 2023 before rising again to 106,513 million US dollars in 2024, reflecting ongoing adjustments in capital deployment or asset base changes.
Economic Spread Ratio
The economic spread ratio, which measures the spread between returns on invested capital and the cost of capital, tracked similarly to economic profit trends. It rose markedly from 4.62% in 2020 to 9.82% in 2021, demonstrating enhanced efficiency or profitability relative to cost of capital. This was followed by a notable decline to 4.76% in 2022 and a further drop to a negative spread of -0.51% in 2023, underscoring operational or profitability challenges that year. The ratio improved to 1.35% in 2024, signaling a modest return to positive value creation, though still substantially lower than earlier peak levels.
Overall Insights
The period under review depicts a company experiencing variable financial performance with a peak in economic profitability in 2021, followed by a downturn and partial recovery. The fluctuations in invested capital suggest strategic adjustments in asset financing or capital allocation. Negative economic profit and economic spread in 2023 indicate a challenging year that affected overall value creation. The modest rebound in 2024 points to an attempt at stabilization or recovery, but values remain below peak performance years. Continued monitoring of these metrics is advisable to assess ongoing financial health and capital efficiency.

Economic Profit Margin

Johnson & Johnson, economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 29, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020
Selected Financial Data (US$ in millions)
Economic profit1
Sales to customers
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2024-12-29), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31).

1 Economic profit. See details »

2 2024 Calculation
Economic profit margin = 100 × Economic profit ÷ Sales to customers
= 100 × ÷ =

3 Click competitor name to see calculations.


Economic Profit
The economic profit exhibited notable fluctuations over the analyzed periods. It nearly doubled from 4,544 million US dollars in 2020 to 9,627 million in 2021, indicating a strong increase in value generation during this interval. However, the following year saw a significant decline to 5,417 million US dollars. In 2023, economic profit turned negative, reporting a loss of 507 million, which suggests operational or market challenges during that period. By the end of 2024, economic profit recovered somewhat but remained modest at 1,435 million US dollars.
Sales to Customers
Sales revenues showed a general upward trend from 82,584 million US dollars in 2020 to a peak of 94,943 million in 2022. However, a noticeable drop occurred in 2023 to 85,159 million US dollars, aligning with the dip in economic profit. Sales then partially rebounded in 2024 to 88,821 million, though it did not reach prior peak levels.
Economic Profit Margin
The economic profit margin mirrored the economic profit trend, with a rise from 5.5% in 2020 to 10.27% in 2021, reflecting increased profitability relative to sales. The margin then declined to 5.71% in 2022 and fell into negative territory (-0.6%) in 2023, coinciding with the negative economic profit. In 2024, the margin returned to positive but remained low at 1.62%, suggesting reduced efficiency or profitability per unit of sales compared to earlier years.
Summary of Trends
Overall, the data indicates a period of strong financial performance peaking around 2021, followed by considerable volatility. Both economic profit and margin experienced significant deterioration in 2023, paralleled by a decline in sales. The partial recovery in 2024 signals some improvement, yet profitability metrics remain below earlier highs. These trends may warrant further investigation into operational factors and market conditions influencing performance fluctuations.